Radiochemotherapeutic options for bladder cancer;Radiochemotherapeutische optionen beim harnblasenkarzinom

Aktuelle Urologie

Volumn 39, Issue 2, 2008, Pages 123-129

  Weiss, C ^a   Sauer, R ^b   Rödel, Claus ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Bladder cancer; Organ preservation; Radiochemotherapy; Salvage cystectomy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BRIDGED COMPOUND; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; GEMCITABINE; TAXANE; TAXOID; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLADDER; BLADDER TUMOR; CANCER STAGING; COMPARATIVE STUDY; CYSTECTOMY; FOLLOW UP; HUMAN; METHODOLOGY; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PREOPERATIVE CARE; RADIATION DOSE; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SALVAGE THERAPY; TIME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; CYSTECTOMY; DEOXYCYTIDINE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MULTICENTER STUDIES AS TOPIC; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREOPERATIVE CARE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SALVAGE THERAPY; TAXOIDS; TIME FACTORS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 42049118278     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1038150     Document Type: Review

References (45)

1. Oosterlinck W, Sylvester R, Böhle A, Rintala E, Solsona Narvón I, Lobel B. EAU Guidelines on TaT1 (Non-muscle invasive) Bladder Cancer: update MARCH 2006. http://www.uroweb.org/fileadmin/user_upload/ Guidelines/05%20TaT1%20Bladder%20Cancer.pdf,
2. Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006; 24: 5536-5544
3. Milosevic M, Gospodarowicz M, Zietman A et al. Radiotherapy for bladder cancer. Urology 2007; 69: 80-92
4. Sauer R, Birkenhake S, Kuhn R et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998; 40: 121-127
5. Rodel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20: 3061-3071
6. Coppin CM, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2901-2907
7. Kent E, Sandler H, Montie J et al. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol 2004; 22: 2540-2545
8. Dunst J, Weigel C, Heynemann H et al. Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer. Strahlenther Onkol 1999; 175 Suppl 3: 7-10
9. Sangar VK, McBain CA, Lyons J et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys 2005; 61: 420-425
10. Muller AC, Diestelhorst A, Kuhnt T et al Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer. Strahlenther Onkol 2007; 183: 177-183
11. Kachnic LA, Kaufman DS, Heney NM et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997; 15: 1022-1029
12. Tester W, Porter A, Asbell S et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993; 25: 783-790
13. Tester W, Caplan R, Heaney J et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase 11 trial 8802. J Clin Oncol 1996; 14: 119-126
14. Shipley WU, Winter KA, Kaufman DS et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998; 16: 3576-3583
15. Zietman AL, Shipley WU, Kaufman DS et al. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 1998; 160: 1673-1677
16. Kaufman DS, Winter KA, Shipley WU et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000; 5: 471-476
17. Hagan MP, Winter KA, Kaufman DS et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 665-672
18. Weiss C, Engehausen DG, Krause FS et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1072-1080
19. Zietman AL, Grocela J, Zehr E et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001; 58: 380-385
20. Weiss C, Wittlinger M, Engehausen DC et al. Management of Superficial Recurrences in an Irradiated Bladder after Combined-Modality Organ-Preserving therapy. Int J Radiat Oncol Biol Phys 2007; epub ahead
21. Weiss C, Wolze C, Engehausen DG et al. Radiochemotherapy after transurethral resection for high-risk t1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol 2006; 24: 2318-2324
22. Kulkarni JN, Gupta R. Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guerin (Danish 1331 strain). BJU Int 2002; 90: 554-557
23. Pansadoro V, Emiliozzi P, de Paula F et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002; 59: 227-231.
24. Brake M, Loertzer H, Horsch R et al. Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer. Urology 2000; 55: 673-678
25. Bogdanovic J, Marusic G, Djozic J et al. The management of T1G3 bladder cancer. Urol Int 2002; 69: 263-265
26. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167: 1573-1583
27. Patard J, Moudouni S. Saint F et al. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 2001; 58: 551-556
28. Gunlusoy B, Degirmenci T, Arslan M et al. Recurrence and Progression of T1G3 Transitional Cell Carcinoma of the Bladder Treated with Intravesical Bacillus Calmette-Guerin. Urol Int 2005; 75: 107-113
29. Peyromaure M, Zerbib M. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int 2004; 93: 60-63
30. Cheng CW, Chan SF, Chan LW et al. 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach. Jpn J Clin Oncol 2004; 34: 202-205
31. Shahin O, Thalmann GN, Rentsch C et al. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003; 169: 96-100
32. Amling CL, Thrasher JB, Frazier HA et al. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 1994; 151: 31-5
33. Freeman JA, Esrig D, Stein JP et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995; 76: 833-839
34. Stockle M, Alken P, Engelmann U et al. Radical cystectomy - often too late? Eur Urol 1987; 13: 361-367
35. Denzinger S, Fritsche HM, Otto W et al. Early Versus Deferred Cystectomy for Initial High-Risk pT1G3 Urothelial Carcinoma of the Bladder: Do Risk Factors Define Feasibility of Bladder-Sparing Approach? Eur Urol 2008; 53: 146-152
36. Harland SJ, Kynaston H, Grigor K et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXMO transitional cell carcinoma of the bladder. J Urol 2007; 178: 807-813
37. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-675
38. Dalbagni G, Genega E, Hashibe M et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001; 165: 1111-1116
39. Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21: 690-696
40. Hautmann RE, Gschwend JE, de Petriconi RC et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006; 176: 486-492
41. Shariat SF, Karakiewicz PI, Palapattu GS et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414-2422
42. Anderstrom C, Johansson S, Nilsson S et al. A prospective randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma. Eur Urol 1983; 9: 142-147
43. Ghoneim MA, Ashamallah AK, Awaad HK et al. Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J Urol 1985; 134: 266-368
44. Smith JrJA, Crawford ED, Paradelo JC et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. J Urol 1997; 157: 805-807
45. Cole CJ, Pollack A, Zagars GK et al. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 1995; 32: 331-340